98 papers
This feasibility study demonstrates that integrating ESPEN evidence-based nutrient guidelines with Ayurvedic concepts of digestive strength is a viable approach to personalizing dietary plans for cancer patients, effectively improving energy intake, diet quality, and malnutrition risk.
This retrospective study of 61 triple-negative breast cancer patients demonstrates that adding the PD-1 inhibitor sintilimab to neoadjuvant chemotherapy significantly improves pathological complete response and objective response rates while maintaining a manageable safety profile compared to chemotherapy alone.
This study introduces a non-invasive method called the Pancreatic Integrated Epigenomic Score (PIES), which utilizes circulating tumor DNA epigenomic profiling to accurately identify pancreatic cancer transcriptional subtypes and improve prognostication compared to traditional tissue-based approaches.
This paper proposes the Backfill Bayesian Ordered Lattice Design (BF-BOLD), a straightforward Phase I clinical trial method that integrates activity evaluation into dose-finding to identify an optimal biological dose, thereby enhancing safety, reducing overdose rates, and improving the selection of the Recommended Phase II Dose without requiring complex statistical modeling.
This study identifies that thin cutaneous melanomas with rapid recurrence are significantly associated with patient age over 65, lentigo maligna subtype, head/neck primary site, mitoses ≥1/mm², and ulceration.
This prospective cohort study of 95,050 UK Biobank participants found that while specific accelerometer-derived physical activity patterns were nominally associated with reduced colorectal cancer risk, these associations largely disappeared after adjusting for lifestyle and metabolic factors, suggesting they are not independent predictors.
This prospective, multicenter observational study in Bogotá, Colombia, aims to validate PINK1 expression as a prognostic biomarker for overall survival, progression-free survival, and functional outcomes in adults with newly diagnosed IDH-wild type glioblastoma multiforme.
This study demonstrates that high-resolution ex vivo diffusion MRI, utilizing advanced metrics like fractional anisotropy and kurtosis, can quantitatively differentiate rectal cancer tissue components and assess treatment response with greater accuracy than conventional T2-weighted imaging, as validated by histological correlation.
The STRONG AYA consortium leverages federated learning to integrate registry data from the UK's Yorkshire Specialist Register of Cancer in Children and Young People with international datasets, transforming it into actionable insights via the PROMPT software to enhance clinical decision-making and patient consultations for adolescents and young adults with cancer.
This study demonstrates that chemoradiotherapy for HPV-related oropharyngeal cancer causes a significant, approximately 25% decline in objectively measured cardiorespiratory fitness, along with reductions in body mass, muscle strength, and quality of life, with these adverse effects persisting at least eight weeks post-treatment.
This retrospective study of an Appalachian lung cancer cohort treated with chemoradiotherapy reveals a high incidence (59%) of cardiovascular adverse events, primarily driven by age and cardiac radiation dose, which machine learning models identified as key predictors despite achieving only modest overall predictive accuracy.
This Phase I clinical study demonstrates that the novel dendritic cell vaccine DOC1021 (dubodencel) is safe and feasible when integrated with standard of care for newly diagnosed glioblastoma, showing promising survival benefits and immune activation that support the initiation of a randomized Phase II trial.
This study presents ThyLNT, a Transformer-based 2.5D deep learning model that significantly outperforms traditional imaging and radiomics methods in preoperatively predicting lymph node metastasis in papillary thyroid carcinoma, while multi-omics analyses validate its predictions by linking them to VEGFA-driven angiogenesis, epithelial-mesenchymal transition, and lipid metabolic reprogramming in the tumor microenvironment.
This study identifies and validates circulating protein signatures that effectively predict severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in relapsed/refractory lymphoma patients prior to CAR T-cell therapy, enabling risk stratification to guide prophylactic interventions and improve patient safety.
This study demonstrates that surplus Faecal Immunochemical Test (FIT) samples remain stable for up to 14 days and yield bacterial 16S rRNA sequencing results comparable to standard whole-stool samples, validating their use for large-scale, low-cost gut microbiota research.
This multi-cohort genomic analysis reveals that the prognostic impact of concurrent TP53 and KRAS alterations is profoundly cancer-type specific, ranging from poor survival in pancreatic and colorectal cancers to improved survival in gastric cancer, driven by distinct mutation subtypes, copy number patterns, co-occurring genetic events, and genotype-expression discordance.
This systematic review and meta-analysis demonstrates that AI/ML-based circulating microRNA signatures show promising diagnostic accuracy for early breast cancer detection, though their routine clinical implementation currently requires further validation through prospective, standardized, and externally validated studies.
This study comprehensively characterizes genomic, transcriptomic, and microbiome differences between African and European ancestry colon cancer patients in New York, revealing ancestry-specific molecular distinctions such as enriched KRAS variants and unique microbial patterns that underscore the critical need for diverse representation in cancer research to improve risk assessment and treatment strategies.
By analyzing multi-omic data from 867 samples, this study demonstrates that antibody-drug conjugate targets in high-grade serous ovarian cancer are broadly stable across space and time, with TACSTD2 and FOLR1 emerging as highly expressed, homogeneous, and frequently co-expressed candidates suitable for therapeutic prioritization.
A retrospective study of 53 patients with advanced cancers, primarily squamous cell carcinomas, found that low-dose nivolumab (20 mg every three weeks) demonstrated encouraging efficacy and manageable toxicity comparable to standard doses, particularly in a frail, elderly population.